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Abstract
The relationship between immune-neuroendocrine system is ﬁrmly established. The messengers of this connection are
hormones, neuropeptides, neurotransmitters and cytokines. The immune-neuroendocrine system have the capacity to
synthesize and release these molecules, which, in turn, can stimulate or suppress the activity of immune or neuroendocrine
cells by binding to receptors. In fact, hormones, neuropeptides and neurotransmitters participate in innate and adaptive
immune response.
Autoimmune rheumatic diseases (ARD) are characterized by aberrant production of pro-inﬂammatory cytokines, which
are a potent activator of the HPA axis. In consequence, high levels of pro-inﬂammatory hormones such as estrogens and
prolactin, and low levels of glucocorticoids, an anti-inﬂammatory hormone, have been described in the active phase of ARD.
In addition, high levels of pro-inﬂammatory hormones and cytokines have also been frequently detected in organ
involvement of patients with ARD, suggesting an abnormal local neuroendocrine immune interaction. There is evidence that
hormonal changes may appear before the symptomatic phase of the disease. Therefore, it is possible that a pro-inﬂammatory
hormone favors the rupture of tolerance, which is a key feature of autoimmune diseases. The interactions between the
immune-neuroendocrine system have a major impact on our understanding of the pathogenic mechanisms, diagnosis and
therapy of ARD.
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The relationship between neuroendocrine and the
immune system has been analysed since the 1980s,
opening new important horizons in the neuroendo-
crine-immune ﬁeld (Weigent and Blalock 1987). It has
been known that the neuroendocrine system can both
directly and indirectly inﬂuence the developmental
and functional activity of the immune system. On the
other hand, the immune system can collaborate in
the regulation of endocrine activity. The network of
connections is mediated by nerve pathways, hormonal
circuits, cytokines, neuropeptides and chemokines
(Szyper-Kravitz et al. 2005). Hormones and neuro-
peptides are secreted not only by endocrine glands but
also by many extra gland sites including the immune
cells, and these molecules can stimulate or suppress
the immune cells by binding to receptors (Besedovsky
and del Rey 1996). Changes in hormonal levels in
autoimmune rheumatic diseases (ARD), could
depend on the enhancement of coordinated bi-
directional communications between neuroendocrine
and the immune systems. High levels of pro-
inﬂammatory hormones such as estrogens (E) and
prolactin (PRL), and low levels of glucocorticoids
(GC), an anti-inﬂammatory hormone, have been
described in the active phase of systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA) and
other autoimmune diseases. High levels of E and
PRL can increase IFN gamma and IL-2 by Th1
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through Th2 lymphocytes activation (Lang 2004; De
Bellis et al. 2005). High levels of pro-inﬂammatory
hormones and cytokines have also been frequently
detected in organ involvement of patients with ARD,
suggesting an abnormal local neuroendocrine immune
interaction (Straub and Cutolo 2001; Elenkov et al.
2005). Of particular interest is the possibility that
a pro-inﬂammatory hormone favors the rupture of
tolerance, which is a key feature of autoimmune
diseases. Furthermore, hormonal changes may appear
before symptomatic phase of the disease (Walker and
Jacobson 2000; Peeva and Zouali 2005). The purpose
of this review is to analyse the role of the immune
neuroendocrine system on inﬂammation and auto-
immune diseases and their interactions during
pregnancy.
Inﬂammation. immune response and
neuroendocrine system
The nervous, endocrine and immune systems orches-
trate a complex and integrated response to stimuli
through interaction of molecules to maintain the
homeostasis (Eskandari et al. 2003). Immune,
endocrine or neural cells can both synthesize and
express receptors for cytokines, hormones, neuro-
transmitters and neuropeptides. These products act in
an autocrine, paracrine and endocrine manner work-
ing as bidirectional feedback communication
mediators (Besedovsky and del Rey 1996). In fact,
hormones, neuropeptides and neurotransmitters
participate in innate and adaptive immune response.
Innate immunity and neuroendocrine system
Hypothalamic-pituitary-adrenal axis. HPA
The innate immunity, the ﬁrst line of immune defense,
involves the mononuclear phagocyte cells that process
antigens and become the primary antigen-presenting
cells (APCs). APCs express on their surface Toll-like
receptors (TLRs) which recognize certain pathogen-
associated molecular patterns (PAMPs) found in
pathogens. TLRs–PAMPs engagement transmits
transmembrane signals that activate the nuclear
factor (NF-kB) and mitogen activated protein kinase
(MAPK) pathways, with transcription of genes
encoding cytokines. The innate immune system had
others resources to recognize microbial pathogen
which include natural killer (NK) cells, gd T cells,
complement system and type I Interferons (IFNs)
(Medzhitov and Janeway 2000; Hansson et al. 2002;
Hoebe et al. 2004). Systemic pro-inﬂammatory
cytokines such as IL-1a/b and IL-6 synthesized by
APC through TLRs pathways, across barriers of the
central nervous system (CNS) to activate in the
circumventricular organs (CVO), and cells forming
the blood-brain barrier. The organum vasculosum of
the laminae terminalis (OVLT) is a region involved in
mechanisms of thermoregulation. Neurons of
the OLVT and the paraventricular nucleus (PVN)
control the corticotrophin-releasing hormone (CRH)
release (Turrin and Rivest 2004). Besides the
hypothalamic-pituitary-adrenal (HPA) axis activation,
cytokines induce a change in the mood, behavior and
pain responses (Eskandari et al. 2003; Turrin and
Rivest 2004; Chida et al. 2005). Therefore, the release
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endogenous mechanisms to suppress the inﬂamma-
tory response genes and the Toll receptor signaling
(Medzhitov and Janeway 2000; Turrin and Rivest
2004) (Figure 1).
GCs exert their immunomodulatory effects through
the glucocorticoid receptor (GR) localized in the
cytoplasm and complexed to heat-shock proteins
(inactive form). The binding of GCs to their
intracellular receptors causes the release of the
complex. The complex steroid/receptors moves to the
nucleus and binds to speciﬁc DNA sequences to
regulategenetranscriptioninterferingwithNF-kBand
activator protein-1 (AP-1) (Sternberg 2006). Recent
evidences suggest that GR represses a set of function-
allyrelatedinﬂammatoryresponsesgenesbydisrupting
p65/interferon regulatory factor (IRF) complexes
required for TLR4- or TLR-9 (Ogawa et al. 2005).
The complement system contributes signiﬁcantly to
theinnateimmuneresponse.ThereceptorC3a(C3aR)
is present on adrenal gland, pituitary, glial cells and
neurons. Francis et al. (2003), hypothesized that
C3a and C3adesArg may activate the HPA axis to
release GC, Growth hormone (GH), PRL and ACTH.
CRH is up-regulated by serotonergic, cholinergic and
catecholaminergic systems. Other neuropeptides such
as g-aminobutyric acid/benzodiazepines (GABA/BZB)
inhibit CRH secretion (Eskandari et al. 2003).
Figure 1. Immune-neuroendocrine system. During inﬂammatory process, active immune system synthesize and release pro-
inﬂammatory cytokines that stimulate the liver to produce acute phase reactants and activation of CNS that leads to the release of
CRH and other neuropeptides by the hypothalamus. CRH increase ACTH production by the pituitary gland, which increase secretion
of GC. The vagus nerve and sympathetic nervous system are other systemic routes to maintain immune-neuroendocrine conections.
Figure modiﬁed from Nat Rev Immunol 2006; 6: 318–328 (reference 16). Toll like receptors (TLR) with PAMPs engagement
transmits transmembrane signals that activate the nuclear factor (NF-kB) with transcription of genes encoding cytokines. IL-1, TNF a
and IL-6 across barriers of the CNS, stimulate neurons of PVN with activation of the HPA axis. The release of glucocorticoids
(GC) is the most powerful endogenous mechanisms to suppress the inﬂammatory response genes and the Toll receptor signaling
cytokines.
Immune-neuroendocrine interactions 111Adaptive immune and neuroendocrine systems
Hypothalamic-pituitary-adrenal axis. HPA
GC inhibit the production of pro-inﬂammatory
cytokines and metalloproteinases and stimulate the
production of anti-inﬂammatory cytokines shifting the
Th1/Th2 balance towards the Th2 phenotype, which
stimulates the humoral immunity. Th2 cytokines are
angiostatic and maintain the integrity of the micro-
vascular system by preserving permeability and
inhibiting adhesion molecules expression limiting
endothelial activation and cell migration to inﬂam-
matory foci (Chikanza and Grossman 2000; Straub
and Cutolo 2001).
Hypothalamic-pituitary-gonadal axis
Females have greater responsiveness of both antibody-
and cell-mediated immune than male. Sex steroids
have binding sites in primary lymphoid organs and
peripheral immune cells, suggesting both Gonado-
trophin-releasing hormone (GnRH) and sex steroids
have a role in immune system, acting through a local
autocrine way and/or through hypothalamic-pituitary-
gonadal (HPG) axis activation. Lymphoid organs and
peripheral immune cells express GnRH and their
receptors (GnRH-R). GnRH is involved in thymus
maturation and has a potent immune-stimulating
action increasing the levels of IL-2R, IFN-g and T
helper cells (Tanriverdi et al. 2003).
Estrogens (E) and androgens (A) inﬂuence immune
cell development in lymphoid tissue and have an
immunomodulatory effect on T and B cells in adult
life. Estrogen receptor (ER) is identiﬁed in mature
peripheral B and T lymphocytes, in contrast with
androgen receptors (ARs) which are absent (Tanri-
verdi et al. 2003). Androgens inﬂuence the size and
composition of the thymus, and have a direct or
indirect effect on enhance suppressor effect increasing
CD42 CD8þ cells. Testosterone (T) inhibits IL-1b
secretion by peripheral blood mononuclear cells
(PBMCs). Dihydrotestosterone (DHT) represses
the expression and activity of the human IL-6 gene.
It is unclear the effects of A on peripheral B cells, but
it seems to diminish the production of autoantibodies
(Tanriverdi et al. 2003). E is an important stimulator
of humoral immunity and they act in both bone-
marrow and peripheral B cells, and the levels of
circulating antibodies (Ab), by increasing IL-10
production. E has effect on T cells, stimulates and
increased CD4þCD82 and CD4þCD8þ cells, and
it can activate an extra-thymic pathway of autoreactive
T cell differentiation. Physiologic concentrations of E
increase the pro-inﬂammatory cytokine production
and pharmacologic concentrations decrease cytokines
synthesis (Straub and Cutolo 2001; Eskandari et al.
2003; Tanriverdi et al. 2003).
Hypothalamic-pituitary-thyroid axis
Thyroid stimulating hormone (TSH) is a central
component of the hypothalamic-pituitary-thyroid
(HPT) axis. Immune cells can be able to produce
biological active TSH. Wang and Klein (2001)
proposed that TSH produced by immune cells during
stress situation, plays a dual role consisting on TSH
communication with immune system and serving to
regulate homeostasis by modulating thyroid hormone
activity. Immune cells have receptors for thyrotrophic
and thyroid hormones (Cremaschi et al. 2000). It has
been observed an increase of T3 and T4 levels after
immunization. In vivo treatment with T4 increases
alloantibodies titer during the early state of alloimmu-
nization, while treatment with propylthiouracil down
regulates the humoral response (Klecha et al. 2000).
The opposed is observed in chronic stress where a
reduction in serum levels of T3, was found. These
ﬁndings suggest that acute and chronic stress induce
an alteration of the HPT axis function that modiﬁed
the adaptive immune response.
Prolactin and immune system
PRL is a 23Kda polypeptide hormone produced by
the anterior pituitary gland that stimulates mammary
growth and differentiation. PRL is stimulated by
suckling and stress and is inhibited by hypothalamic
dopamine. This hormone is produced in a number of
sites outside the pituitary, including the brain and
immune cells. PRL is important in maintaining
immune competence and has a role in the
pathogenesis of ARD. All activities of PRL are
mediated by the PRL-receptor, a member of the
hematopoietin cytokine receptor superfamily (Walker
and Jacobson 2000; Szyper-Kravitz et al. 2005). PRL
expression and PRL-receptors have been demon-
strated in immune cells suggesting that the hormone
may act in an auto- or paracrine way. PRL stimulates
inducible nitric oxide (NO) syntheses production, Ig
release and cytokine expression in human leukocytes
(Lahat et al. 1993; Matera et al. 1999; Matalka
2003). PRL is a T cell mitogen through the PRL-
R/Janus activating kinase (JAK)/Stat/IRF-1 signaling
pathway and NF-kB signals (Yu-Lee 2002). T
lymphocytes PRL expression is subject to regulation
by cytokines. Both IL-2 and IL-4 reduced PRL
mRNA levels in T lymphocytes (Gerlo et al. 2005).
PRL signiﬁcantly enhanced the expression of CD69,
CD25 and CD154 and cytokines secretion, and
modulate B cells development (Morales et al. 1999;
Chavez-Rueda et al. 2005; Takizawa et al. 2005).
Therefore, PRL has an important role in adaptive
immune response.
After inﬂammatory challenge an immediately raise
of serum GC, epinephrine and norepinephrine is
observed. However, a prolonged increased in the
L. J. Jara et al. 112activity of the HPA axis conduce to a prompt lost
of the anti-inﬂammatory mediators with increase
of pro-inﬂammatory mediators such as PRL, 17-
b-estradiol (E2) and substance P (Straub and
Besedovsky 2003).
The concept of an integrated bidirectional
regulated neuroendocrine-immune adaptive response
to stress has strong experimental support (Wilder
1995). In this regard, Ezzat et al. (2005), identiﬁed
expression of Ikaros transcription factors (a differ-
entiation factor of leukocytes lineage), in mouse
pituitary cells and demonstrated a direct role for
Ikaros in the regulation of ACTH expression and
adrenocortical hormone production. Ikaros inﬂuence
the maturation of the fetal pituitary corticotrophin
and the secretion of ACTH before and after birth
indicating that it is an integrator of the stress and
immune systems, and their defects may produce
endocrine and/or immune diseases (Chrousos and
Kino 2005).
Hypothalamic pituitary adrenal axis and
autoimmune rheumatic diseases
Rheumatoid arthritis
RA is mediated by high levels of pro-inﬂammatory
cytokines, which are a potent activator of the HPA
axis. In consequence, the endogenous GCs produced
by the adrenal glands, have an important role in the
inﬂammation cascade in RA (Morand and Leech
2001).
Animal models. The classic studies of Sternberg et al.
(1989) using a model with Lewis and Fisher strain of
rats (the former is inﬂammatory-susceptible and the
latter is resistant), demonstrated that in Lewis rats,
susceptibility to inﬂammatory disease is related to
blunted HPA axis response, whereas Fisher rats have
exaggerated response. Recently, this hypothesis was
challenged. Chover-Gonzalez et al. (2000) observed
that in high-stress situations, rats with a greater
corticosterone response to the acute stress developed
early and more severe arthritis than rats with a less
profound corticosterone response, suggesting that the
balance of pro- and anti-inﬂammatory factors released
in response to stress may inﬂuence the progress of
adjuvant arthritis (AA). In another study, Lewis rats
were divided in high-active (HA) and low-active (LA)
animals based on their exploratory activity in the open
ﬁeld. The AA activity in the open ﬁeld was associated
with the severity of bone destruction, low production
of bone-protective cytokines (IL-10 and IFN-g), and
high levels of vascular endothelial growth factor
(VEGF), leading to more synovial proliferation in
LA animals. Of interest, there were no differences
between HA and LA rats in corticosterone response
after acute or chronic immune challenge (Sajti et al.
2004).
Human studies. The most persuasive evidence was
provided by the observation that clinical signs of
inﬂammation in RA could be exacerbated by the
administration of metyrapone, an 11b-hydroxylase
inhibitor that inhibits adrenal GC synthesis (Morand
and Leech 2001). Lost of cortisol circadian rhythm
has been reported in patients with high activity RA
(Neeck et al. 1990). Chikanza et al. (1992)
demonstrated in RA patients a failure to increase
cortisol secretion following surgery, despite high levels
of interleukin-1 b (IL-1b) and IL-6. These patients
had a defective HPA response, as evidenced by a
diurnal cortisol rhythm of secretion which was at the
lower limit of normal, in contrast to those patients
with osteomyelitis. CRH stimulation test in RA
patients showed normal results, suggesting a
hypothalamic defect. The key question that remains
unanswered is whether the HPA-axis abnormalities
seen in humans with RA are a predisposing factor or a
consequence of the disease. The examination of case
reports, such as those of RA onset after treatment of
Cushing’s disease, leads to a strong suspicion of HPA
axis function as a barrier to the development of RA,
which once breached permits this disease to ensue
(Uthman and Senecal 1995; Straub and Cutolo
2001). Signiﬁcant dissociation of serum cortisol and
dehydroepiandrosterone sulfate (DHEAS) levels
was found in the subgroup of asymptomatic
premenopausal women who developed RA before
age 50 (Masi et al. 2000; Masi et al. 2005). Gutierrez
et al. (1999) showed that active RA is associated with
subtle dysfunction of the HPA and normal PRL
secretion. Using the insulin tolerance test, RA patients
have decreased plasma cortisol levels compared to
healthy controls, despite elevated levels of IL-6. The
defect is probably located at the adrenal level and may
be of pathogenic signiﬁcance for the development of
RA (Eijsbouts et al. 2005).
One way for the study of immune neuroendocrine
interactions is through speciﬁc membrane receptor
for GC (mGR) on RA lymphocytes. Measurement of
mGR has produced contrasting results from slightly
elevated to decreased numbers of GRs in PBMCs in
RA (Schlaghecke et al. 1994; Bartholome et al.
2004). Neeck et al. (2002) using immunoblot
analysis to detect mGR in lymphocytes of untreated
RA patients, GC-treated RA patients and healthy
controls found that untreated RA patients exhibited a
signiﬁcantly higher amount of mGR, whereas GC-
treated RA patients showed a strongly decreased
receptor density. These results suggest a functional
dysregulation of the HPA axis. mGCR are localized
not only on inﬂammatory lymphoid cells of RA
patients, but also on synoviocytes, suggesting that




axis response to recombinant human (rhu) IL-1a in
lupus-prone mice. This model produced nearly the
same levels of plasma corticosterone after injection of
rhu-IL-1alphaasseeninnormalmice,buthadbaseline
corticosteronelevelsconsistentlyhigher(Lechneretal.
1996). MRL/MP-fas (Lpr) mice not only show an
altered GC response mediated via HPA axis, but are
also affected by disturbance of GC and melatonine
circadian rhythms.These results conﬁrm the existence
of a disturbed immunoendocrine communication
in lupus-prone mice (Lechner et al. 2000). Shanks
et al. (1999) showed a decrease in hypothalamic
CRH mRNA expression and an increase in arginine-
vasopressin (AVP) mRNA expression associated with
increased autoantibody levels, and disease progression
in a SLE murine model.
Human studies. Zietz et al. (2000) investigated ACTH,
androstenedione (ASD), cortisol, or DHEAS before
and during a CRH test in patients with moderately
active SLE treated with low dose of GC therapy, and
their relation to IL-6 or TNF. They found marked
adrenal insufﬁciency and a shift in steroidogenesis to
cortisol in SLE patients; but a completely normal
pituitary function. This ﬁnding depends in part of GC
therapy.
The cortisol response after hypoglycemia was
signiﬁcantly lower in active SLE suggesting some
degree of HPA axis dysfunction (Gutierrez et al.
1998). Recently the total anterior pituitary reserve was
investigated in SLE before the initiation of GC or
immunosuppressive treatment. Surprisingly no sig-
niﬁcant alteration of the HPA axis was found in SLE,
which is inadequate due to continuing inﬂammation
(Ko ¨ller et al. 2004).
Straub et al. (2004) demonstrated in RA and SLE
patients that low serum levels of adrenal androgens
and cortisol were not due to increased renal clearance.
Decreased adrenal production or increased conver-
sion or conjugation to downstream hormones was the
most likely in RA and SLE patients (Straub et al.
2004). Patients with SLE had increased neuropeptide
Y levels. In contrast, plasma ACTH and cortisol levels
were decreased in SLE and RA. This study displayed
an increased outﬂow of the sympathetic nervous
system and a decreased tone of the HPA axis in
patients with SLE and RA (Harle et al. 2006).
Gladman et al. (1991) found that mGCR of
leukocytes of SLE patients were signiﬁcantly high
without correlation with disease activity. However,
other studies showed that mGCR was associated with
active SLE (Tanaka et al. 1992). Polymorphism
analysis revealed a single mutation in exon 9 of the
mGR gene in SLE patients (Lee et al. 2004). Finally,
Spies et al. (2006) investigated the expression of
mGCR and demonstrated that these are up-regulated
in SLE-patients and down-regulated by GC.
Sjo ¨gren syndrome
To investigate HPA axis in Sjo ¨gren syndrome (SS), the
ACTH response to ovine CRH (oCRH) has been used
as a direct measure of corticotrophic function, and the
plasma cortisol response to the ACTH released during
oCRH stimulation as an indirect measure of adrenal
function. Patients with SS were characterized by
signiﬁcantly lower ACTH and cortisol levels, respect-
ively. Furthermore, a blunted pituitary and adrenal
response to oCRH was observed, indicating a
relatively hyporesponsiveness of the adrenal gland to
CRH stimulation. These ﬁndings indicate hypoactiv-
ity of the HPA axis in patients with SS (Johnson et al.
1998; Johnson et al. 2000).
In conclusion, dysfunction of HPA-axis in patients
with RA, SLE and SS seems to be important in the
pathogenesis of these diseases. In RA the accumulated
evidence strongly supports the viewpoint that HPA-
axis is deﬁcient. Surprisingly, few studies have directly
evaluated the HPA axis in SLE compared with healthy
controls. Because of the small number of studies
and patients, the results must be considered with
caution (Li et al. 2005). The few studies available in
SS patients have indicated a central deﬁciency in
HPA axis.
The hypothalamic pituitary gonadal axis and
autoimmune rheumatic diseases
The HPG axis and sex hormones have an important
immunoregulatory role. Physiological concentrations
of E enhance immune responses, on the contrary,
progesterone (PG) and A, such as T and DHEA,
are natural immunosuppressors (Cutolo and Wilder
2000; Eskandari et al. 2003). Animal models
demonstrated in vivo modulation of the immune
system by E receptors. Knockout mouse models to E
receptors a and b, indicate that both are important for
thymus development and atrophy (Erlandsson et al.
2001).
HPG and stress
Immune stress has an inhibitory effect on the HPG
axis and thus gonadal function is reduced in severe
inﬂammation. It is mediated through a direct cytokine
effect on hypothalamic neurons secreting luteinizing
hormone or CRH, endogenous opioids and also by the
cytokines action directly on the gonads (Rettori et al.
1991).
L. J. Jara et al. 114Estrogens and autoimmune diseases
Several physiological, pathological and therapeutic
conditions may change the serum estrogen milieu
and/or peripheral conversion rate, including the
menstrual cycle, pregnancy, postpartum period,
menopause, elderly, chronic stress, inﬂammatory
cytokines, use of corticosteroids, oral contraceptives
and steroid hormonal replacements, including andro-
gen/estrogen ratios and related effects (Cutolo et al.
2004).
Animal models
Experimental studies try to explain the mechanisms by
which E enhance the immune/inﬂammatory response
exerted by activating the NF-kB complex pathway.
Locally increased E may produce activating effects on
synovial cell proliferation, including macrophages and
ﬁbroblasts (Cutolo et al. 2003). Macrophages release
cytokines can be modulated by E in different ways. Fcg
receptor type IIIA (CD16a) is expressed on macro-
phages that selectively bind IgG molecules. Binding of
CD16 by anti-CD16 monoclonal Ab stimulates
macrophage cytokine release. E also modulate pro-
inﬂammatory cytokine release from activated mono-
cytesor macrophages through the modulation ofCD16
expression (Kramer et al. 2004). There is evidence for
thedirecteffectofE2onB-cellfunctioninexperimental
lupus,throughthebreakofB-celltolerancethatinducea
lupus-like phenotype in non-autoimmune mice (Bynoe
et al. 2000). Grimaldi et al. (2001) demonstrated that
E2 treatment of BALB/c mice transgenic for the heavy
chainofapathogenicanti-DNAAbinducesalupus-like
phenotype with expansion of anti-DNA B cells,
elevation of anti-DNA Ab titers and glomerular
immunoglobulin deposition. A sustained increase in
E2 resulted in an altered distribution of B cell subsets,
with a diminished transitional population and an
increase in marginal zone B cells. Recent data provide
evidence that E2 facilitates the maturation of a
pathogenic naive autoreactive B cell repertoire and
hampersthematurationofapotentiallyprotectiveBcell
repertoire. These data show that both, positive and
negative selection occur within the transitional B cell
stage under the inﬂuence of E2 in this model (Grimaldi
et al. 2006).
ThemodelofEdeﬁciencyinrodentsisthearomatase-
knockout (ArKO) mouse. A recent report showed that
ArKO mice with E deﬁciency develop severe auto-
immuneexocrinopathyresemblingSS,andsuggestthat
E might have clinical value in the prevention or
treatment of this disease (Shim et al. 2004).
Human studies
Clinical studies suggest a role for E in ARD. Elevated
serum concentrations of 16a-hydroxyestrone have
been described in patients with SLE, suggesting that
abnormal patterns of E metabolism may lead to
increased estrogenic activity (Lahita et al. 1979).
Increased E formation and E/A ratio in the synovial
ﬂuid of RA patients have been demonstrated,
probably due to increased aromatase activity (Cas-
tagnetta et al. 2003). Tengstrand et al. (2003) showed
decreased DHEAS and estrone concentrations and
increased E2 levels in male patients with RA. E2
correlated with indices of inﬂammation. In addition,
RA and SLE patients have a shift to mitogenic E such
as 16a-hydroxyestrone in relation to endogenous
antiestrogens, which contributes to maintenance of
the proliferative state in these diseases (Weidler et al.
2004). The relationship between E and E receptors
(ER) may play a role in the patoghenesis of SLE. ERa
and ERb are expressed in immune cells. A recent
study shows that ERa codon 594 genotype may
inﬂuence the development of SLE at a younger age
(Kassi et al. 2005). In primary Sjo ¨gren syndrome
(pSS) the relations with E are not clear. In a study,
higher levels of disease activity were associated with
higher concentrations of T without correlation
between E levels (Brennan et al. 2003). The apoptotic
pathway may play a central role in tolerant T cells to
tissue-speciﬁc self antigen, and may drive the
autoimmune phenomenon. T exerted pro-apoptotic
effects and reduced macrophage proliferation,
whereas E2 induced anti-apoptotic effects by inter-
fering with NF-kB activities (Cutolo et al. 2005).
In vitro apoptosis of PBMCs in short-term unstimu-
lated cultures of SLE cells is accelerated compared to
normal individuals; however, E decrease in vitro
apoptosis (Evans et al. 1997). Another study mentions
apoptosis and E deﬁciency in pSS with possible
antiestrogenic actions as a potent factor in the
formation of pathogenic autoantigens (Hayashi et al.
2004). Two patients who received E therapy deve-
loped SS, suggesting that E may play a role in the
pathogenesis of SS in some patients (Nagler and
Pollack 2000).
Androgens and autoimmune disease
DHEAS and related steroid hormones have a variety
of immunological effects both in vitro, experimental
models, and humans (Dillon 2005).
Animal models
Autoimmune mice models show effects of A on
immune maturation reﬂected by the expression of
receptors for E and DHT, effects on the size and
composition of the thymus, inhibition of B cells and
T-cells maturation, and reduce synthesis of immuno-
globulins. On monocytes, androgens decreased IL-6
and IL-1 production and on macrophages inhibit IL-1
(Ahmed et al. 1985; Grossman 1988). T speciﬁcally
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upgrading TNF-a production (Guevara Patino et al.
2000). Michalski et al. (1983), reported that A
therapy in B/W mice is associated with improve cell-
mediated immune function and increase survival.
Androgen may prolong survival in this model through
an effect on anomalous suppressive regulatory cells
that impaired T lymphocytes function (Verthelyi and
Ahmed 1994).
Human studies
Human studies show low gonadal and adrenal A levels
as well as reduced A/E ratio, detected in body ﬂuids
such as blood, synovial ﬂuid, smears, saliva of male
and female RA patients, supporting the possible role
of gonadal hormones on the RA pathogenesis (Cutolo
et al. 2002). Identiﬁcation of functional A receptors in
synoviocytes and the modulatory effect of DHTon the
inﬂammatory process in the joint suggest a direct link
between hypoandrogenicity and RA disease status
(Khalkhali-Ellis et al. 2002). Deﬁciency of DHEA and
DHEAS has been associated with other illnesses,
therefore, some investigators have said that SLE in
men are the result of too little A and too much E
(Inman et al. 1982), however most studies indicate
that men with SLE have normal levels of A and E/A
ratios might be minimally elevated in some men;
studies of A metabolism in women with SLE indicate
that a difference in the overall metabolism of A can be
found in this gender (Lahita 2000). Male RA patients
have hypogonadism with low levels of luteinizing
hormone, suggesting a central origin of the relative
hypoandrogenicity (Tengstrand et al. 2002). There is
controversy about the role of A in male patients with
ankylosing spondylitis (AS). Gooren et al. (2000)
found elevated DHEAS and 17 alpha-hydroxypro-
gesterone levels in AS patients and it may be
secondary to inﬂammation and stress, or causally
related to AS. However, other studies reported no
alterations of serum levels of adrenal and gonadal
hormones in patients with AS. The impact of sex
steroids on AS is still unresolved (Straub et al. 2002).
Other ARD in which low levels of DHEAS have been
reported are pSS and polymyalgia rheumatica
(Valtysdottir et al. 2001; Cutolo et al. 2002). In
summary, sex hormones play an important role on
ARD, depending on the physiological or supraphysio-
logical concentrations, under stress conditions and
other factors. The effects of estrogens and androgens
are shown in Table I.
Prolactin and autoimmune rheumatic diseases
In 1930, Smith observed in rats thymus atrophy after
hypophysectomy. This was the ﬁrst study to indicate
the role of PRL in thymic physiology. However, until
1980s the relationship between PRL and the immune
system was analysed. The classic studies of Berczi and
Nagy (1982) showed that PRL is involved in the
pathogenesis of AA and it restores immunocom-
petence in hypophysectomized or Bromocriptine
(BRC) treated rats. Elevated PRL serum levels in
AA, collagen type II-induced arthritis, murine and
human SLE, and autoimmune type I diabetes may
inﬂuence the outcome of the disease. It has been
suggested that hyperprolactinemia (HPRL) is a risk
factor for the development of autoimmunity and ARD
(Jara et al. 1991; Neidhart 1998).
Animal models
The role of PRL in murine SLE and pituitary
transplantation was studied by McMurray et al.
(1991). HPRL was associated with increased IgG
concentrations, anti-DNA Ab, immune complex,
glomerulonephritis and accelerated mortality. BRC-
induced suppression of PRL was associated with
decreased of disease activity, and prolonged lifespan.
BRC also was beneﬁcial in a murine model of primary
antiphospholipid syndrome (Blank et al. 1995).
Autoimmune disease acceleration by PRL is incre-
mented by E stimulation (McMurray 2001). To
identify whether E effects reﬂect increased PRL
secretion, Peeva et al. (2000) showed that treatment
of transgenic mice with E plus BRC led to reduced
titers of anti-DNA Ab and diminished IgG deposition
in kidneys compared with treatment with E alone.
The E-induced breakdown in B-cell tolerance can be
abrogated by BRC. On the contrary, treatment
with PRL induced a lupus-like phenotype with an
increased number of B cells, elevated serum anti-
DNA Ab, and glomerulonephritis (Peeva et al. 2003).
The spleens of treated mice displayed that marginal
Table I. Estrogen and androgen effects on immune function.
Estrogens Androgens
Stimulation of polyclonal B-cell activity B-cell precursor depletion in bone marrow
Reduction of phytohemagglutinin response Supress the phytohemagglutinin-induced blast transformation of lymphocytes
Enhanced mixed lymphocyte reaction Thymic atrophy, thymocyte apoptosis
Enhances bone marrow graft rejection Delay graft rejection in animal models
Enhances TH2 pathway Enhances suppressor T cells
Increases the release of inﬂammatory cytokines Decreases cytokine production
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Anti-DNA B cells in E-treated mice become marginal
zone cells while identical cells from PRL-treated mice
become follicular cells (Venkatesh et al. 2006). Taken
together, these ﬁndings support the hypothesis that
PRL and E favors the rupture of immune tolerance,
which is a key feature of ARD.
Human studies
Human PRL observations in ARD, particularly in
SLE, preceded to murine SLE studies. The ﬁrst report
of HPRL in SLE was in men (Lavalle et al. 1987).
This ﬁnding was conﬁrmed by other studies. HPRL
has been found in 20–30% of patients with SLE
particularly in those patients with active diseases (Jara
et al. 1992; Walker and Jacobson 2000). There is
controversy if HPRL is associated with active SLE
(Buskila et al. 1996; Jimena et al. 1998). This
discrepant ﬁnding may be explained by different
factors such as: statistical power of these studies
(Blanco-Favela et al. 1999), heterogeneous groups of
patients, variability of the SLE activity indices used,
different treatments, abnormal circadian rhythms of
PRL, anti-PRL Ab, etc. (Jara et al. 2001). SLE
patients with anti-PRL Ab could be the cause of
HPRL in a subset of SLE patients (Leanos et al.
1998). New evidence has conﬁrmed a signiﬁcant
correlation between bioactive and immunoreactive
PRL levels and SLE activity (Jacobi et al. 2001;
Leanos-Miranda et al. 2001; Pacilio et al. 2001).
Regardless of this controversy, human studies
suggest that PRL can participate in major and minor
organ involvement such as lupus nephritis, neuropsy-
chiatry lupus, joint and cutaneous lupus (Jara et al.
1998; Miranda et al. 1998; Vera-Lastra et al. 2003).
Similar observations have been described in synovium
inﬁltrating T cells in RA (Nagafuchi et al. 1999).
These clinical observations suggest that PRL may be
produced in organ affected from SLE and others
ARD, by inﬁltrating lymphocytes.
In this regard, PBMCs from patients with active
SLE have increased production of PRL-like immuno-
reactive substance with different molecular weight:
11, 60kDa and it seems to be derived from B
lymphocytes (Gutierrez et al. 1995; Larrea et al.
1997). PRL with 130 and 23kDa were associated with
inactive SLE (Cruz et al. 2001). An increase in serum
free PRL levels, with high levels of little PRL and low
levels of big/big PRL was associated with lupus activity
(Leanos-Miranda and Cardenas-Mondragon 2006).
In contrast, other study showed that patients with
increased big/big form had a very active illness (Garcia
et al. 2004).
The exact origin of HPRL in SLE patients is
unknown and these studies suggest that active SLE
lymphocytes may be the source of PRL. In support of
this hypothesis, we found a signiﬁcant decreased of
PRL concentrations following treatment with immu-
nosuppressive drugs (Vera-Lastra et al. 2003), SLE
lymphocytes synthesize PRL and have alterations in
the CREB family proteins, which participate in
lymphocyte PRL gene expression (Gutierrez et al.
1995; Larrea et al. 1997; Montgomery 2001) and a
functionally signiﬁcant polymorphism is over
expressed in SLE lymphocytes (Stevens et al. 2001).
Lymphocyte-derived PRL might contribute to alter
the functional activity of the hypothalamic dopamin-
ergic system in SLE attempting to maintain serum
PRL within a physiological range (Mendez et al.
2004). These evidences provide a potential expla-
nation for the increased PRL release by SLE
lymphocytes. However, is not known if lymphocytes
can produce enough PRL to cause an increase in
serum PRL levels. In this regard, it has been
demonstrated HPRL and PRL-immunostaining in
bone marrow cells of patients with multiple myeloma.
PRL-immunopositive bone marrow cells disappeared
and serum PRL normalized after treatment (Gado
et al. 2001). This study suggests that B lymphocytes
are the source of HPRL in multiple myeloma.
HPRL is associated with several Ab involved in SLE
such as ANAs, anti-dsDNA, anticardiolipin Ab, etc.
and hypocomplementemia. PRL induces immunoglo-
bulin synthesis and anti-dsDNA by SLE lymphocytes.
Of interest, the physiological concentrations of PRL
(20ng/ml) induced IgG production more effective
than PRL at 100ng/ml (Vera-Lastra et al. 2002).
HPRL in SLE and RA is associated with antithyroid
Ab, evidencing the association of PRL and auto-
immunity (Kramer et al. 2005).
The role of PRL in the lymphocytes activation in
active and inactive SLE was studied in an in vitro
model. CD69 expression was associated with disease
activity. In contrast, CD154 did not show this
association. Mononuclear cells were capable of
producing and secreting PRL and to express PRL-
receptor (Chavez-Rueda et al. 2005).
Of interest, the PRL gene is in close proximity to the
HLA region on the short arm of chromosome 6.
Linkage disequilibrium between HLA–DRB1 (alleles
associated with SLE and RA susceptibility) and PRL
genes (Brennan et al. 1997) has been described. This
report provides an immunogenetic base to explain the
relationship between SLE and PRL. However, a
recent analysis of PRL and PRL-receptor genes
polymorphism in SLE and multiple sclerosis did not
ﬁnd statistically signiﬁcant difference in the allele
distribution (Mellai et al. 2003).
HPRL was found in patients with RA, reactive
arthritis, systemic sclerosis (SSc), Sjogren syndrome
and juvenile chronic arthritis (Walker and Jacobson
2000). Patients with AS had signiﬁcant lower serum
levels of osteocalcin and higher levels of serum T, LH
and PRL (El Maghraoui et al. 2005). Recently, we
analysed the status of the hypothalamic dopaminergic
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prevalence of pituitary adenomas in SSc. A group of
patients with SSc have a high prevalence of HPRL
with increased central dopaminergic tone, and
microadenomas (Vera-Lastra et al. 2006). In this
regard, microadenomas have been found in patients
with SLE and other rheumatic diseases. Patients with
long-standing HPRL secondary to microadenoma
may develop SLE. In some patients, SLE onset was
preceded by withdrawal or tapering BRC (Walker and
Jacobson 2000; Jara et al. 2001). The ﬁrst pediatric
case of prolactinoma associated with SLE, in a 13-
year-old white female was reported. Neurosurgical
resection and medical therapy with BRC were
independently associated with decreased PRL levels
and remission of clinical and serological SLE
manifestations (Reuman 2004). Three other patients
with SLE and prolactinomas have been reported
without ﬁndings related to HPRL or its association
with SLE ﬂares. This may be due to genetic
differences in the response to PRL and/or to the
presence of variant PRL isoforms that have reduced
biological activity (Li et al. 2006). Finally, a patient
with hypocomplementemic urticarial vasculitis, Jac-
coud’s arthropathy, SLE and Sjogren syndrome in
association with HPRL secondary to pituitary micro-
adenoma has been described. The genetic studies of
this patient disclosed HLA class II DRB1* 0301
QDB1* 0201. The combination of genetic suscepti-
bility, female gender, multiple autoimmune disease
and HPRL represent a classic example of the concept
of autoimmunity developing as a mosaic (Anaya and
Shoenfeld 2005).
In conclusion, in vitro experimental models and
clinical evidences strongly support the role of PRL in
the pathogenesis and clinical manifestations of SLE
and other ARD.
Immune neuroendocrine system, pregnancy and
autoimmune rheumatic diseases
Endocrine regulation of fetal growth involves inter-
actions between the mother, placenta and fetus, and
these effects may program long-term physiology
(Murphy et al. 2006). Many hormones are increased
during pregnancy such as CRH, pro-opiomelanocor-
tin, ACTH, cortisol, E, PG, PRL and human
placental lactogen. The increases of E, PG and GC
during pregnancy are associated with increased
production of Th2 cytokines, and decreased pro-
duction of Th1 cytokines. These patterns reverse in
the postpartum period (Kanik and Wilder 2000).
Evidence acquired from clinical data and experimen-
tal animal models suggest that Th1 cytokines are
detrimental to pregnancy while Th2 cytokines, are
protective (Wegmann et al. 1993). Detection of IL-15
and IL-18 at the placental level suggest that
interactions between cytokines and hormones is
more complex that the Th1/Th2 paradigm to explain
the pregnancy course. IL-15 has been implicated in
differentiation and proliferation of uterine NK cells,
whileIL-18enhancedinnateimmunity(Laskarinetal.
2005). The effects of cytokines on reproductive events
led to the “immunotrophism” model, which suggests
that maternal immune recognition of fetal-derived Ags
results in the release of cytokines that promote the
growth of the placenta (Tangri et al. 1994). During
pregnancy there is an up regulation of PG receptors
on activated lymphocytes among placental cells and
decidual CD56þ cells. In presence of sufﬁcient PG,
these cells synthesize progesterone induced blocking
factor (PIBF), a mediator that exerts substantial anti-
abortive activities. PIBF affects B cells and induces an
increased production of non-cytotoxic Ab and it also
alters the proﬁle of cytokine secretion by activated
lymphocytes resulting in an increase in the production
of non-inﬂammatory, non-cytotoxic cytokines and a
reduction in the production of inﬂammatory, cyto-
toxic cytokines (Druckmann and Druckmann 2005).
Only in pregnancy experimental models, there are
detailed studies regarding the responsiveness to the
stressors of the HPA axis. In late pregnant rats and
during lactation, HPA axis is hypo responsive to
psychogenic stressors (Neumann et al. 1998) and the
responses to immune signals (LPS, IL-1) are sup-
pressed. In situ hybridization revealed decreased CRH
and pro-opiomelanocortin mRNA expression in the
hypothalamus. In contrast, proenkephalin-A and mu-
opioid receptor mRNA expression in the nucleus
tractus solitarius (NTS) was signiﬁcantly increased in
pregnantrats,indicatingthattheHPAaxisresponsesto
immune signals are suppressed in pregnancy at the
level of hypothalamic CRH neurons through an opioid
mechanism (Brunton et al. 2005). Additionally,
activation of neuropeptidergic systems such as oxyto-
cin and PRL, which are necessary for reproductive
processes (labor, lactogenesis, maternal behavior),
may be involved in the inhibition of ACTH and GC
secretory responses (Neumann et al. 2003). These
adaptations preserve the oxytocin store for parturition
and prevent pre-term birth (Russell and Brunton
2006). PRL has recently been shown to exert an
anxiolytic effect and an inhibitory tone on HPA axis
activity in pregnancy and lactation with increased
expression of the hypothalamic PRL gene, suggesting
an activated state of PRL during the peripartum
period.Activation ofthePRLintheperipartumperiod
signiﬁcantly contributes to emotional and neuroendo-
crine adaptations, with down regulation of the
responsiveness of the HPA axis (Torner et al. 2002).
In 1991, we demonstrated that gonadal hormones
and PRL alterations during pregnancy are present in
SLE patients. These changes may be related to fetal
wastage and disease activity. Signiﬁcant lower serum
E2 and testosterone with higher PRL levels in
pregnant patients with SLE were found (Jara-Quezada
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pregnancy conﬁrmed the association of PRL with
pregnant lupus disease activity (Petri and Chan 1995).
Doria et al. (2002), conﬁrmed the variation of steroid
hormone levels during pregnancy in patients with
SLE. Disease activity score signiﬁcantly varied during
pregnancy and postpartum In SLE patients, E2, PG
and DHEAS concentrations were found to be
signiﬁcantly reduced. This ﬁnding probably was due
to placental insufﬁciency. These steroid hormone
variations may result in a lower humoral immune
response activation, which in turn could account for
the decrease in disease activity observed during the
third trimester in pregnant SLE patients.
McMurray et al. (1993) developed elegant animal
experiments. Pregnancy, with or without suckling and
pseudopregnancy induced long-term HPRL, which
accelerate the appearance of anti-DNA Ab to the viral
protein gp70, hypergammaglobulinemia and disease
activity. Taken together, clinical and experimental
results leave little doubt that in pregnancy SLE, PRL
indeed contributes to the pathogenesis of disease
(Berczi 1993).
A reduction in the incidence and severity of RA
is seen in pregnant women. Relaxin, a hormone of
pregnancy, has been implicated in decreased immune
responsiveness. Relaxin and estradiol valerate therapy
reduced AA (Santora et al. 2005). In a prospective
study in RA, SLE and normal pregnant women,
TNFa was found in all groups studied. High IL-10
levels were found in RA and SLE patients. This study
showed decreased cortisol levels in all patients.
Immune and hormonal networks are involved in
pregnancy and ARD and these are very dynamic
immune processes (Munoz-Valle et al. 2003).
The risk of RA seems to be associated with reduced
fecundity and with breastfeeding; these apparently
contradictory risk factors can be explained by their
association with high PRL concentrations. The effects
of breastfeeding and nulliparity are modiﬁed by HLA
DR4 status, suggesting an interaction between genetic
and reproductive risk factors in the etiology of RA.
The associations between DR4 and reproductive
risk factors in RA are due to linkage disequilibrium
between DR4 and an abnormally regulated PRL gene
polymorphism (Brennan et al. 1996).
During pregnancy, experimental models and
patients with ARD develop an abnormal immune-
neuroendocrine response. In SLE, the contribution
of E, PG, A and PRL may inﬂuence to successful or
pathologic pregnancy. However a multitude of ques-
tions remain to be investigated (McMurray 2002).
Conclusion and perspectives
Studies accumulated from two decades ago and
during the last years support a role of immune-
neuroendocrine system in the pathogenesis and
clinical expression of ARD. During inﬂammatory
stimuli, the interaction among HPA, HPG, HPTand
PRL-gonadal axis with immune system is abnormal in
patients with ARD, particularly during active disease.
Table II shows the alterations of neuroendocrine
system in ARD. The ARD are caused by a failure of
immune cells tolerance, and the abnormal response of
immune-neuroendocrine system may participate in
the break of tolerance. These ﬁndings have impli-
cations for the treatment of autoimmune disease.
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